This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow An erratum has been published
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, B.
Right arrow Articles by Orme, I. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, B.
Right arrow Articles by Orme, I. M.

 Previous Article  |  Next Article 

Clinical and Vaccine Immunology, July 2007, p. 902-906, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00077-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.

A Toll-Like Receptor-2-Directed Fusion Protein Vaccine against Tuberculosis{triangledown}

Baolin Wang,{dagger} Marcela Henao-Tamayo,{dagger} Marisa Harton, Diane Ordway, Crystal Shanley, Randall J. Basaraba, and Ian M. Orme*

Mycobacteria Research Laboratories, Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado

Received 6 February 2007/ Returned for modification 7 March 2007/ Accepted 9 May 2007

A fusion protein designated CSU-F36 was constructed that consisted of acylated Rv1411, a potent Toll-like receptor-2 agonist, fused to ESAT-6, a well-characterized immunogenic protein from Mycobacterium tuberculosis. The CSU-F36 fusion protein strongly induced interleukin 12 secretion from macrophages and induced the increased accumulation of CD4 T cells capable of secreting gamma interferon in the lungs of infected mice. These mice were significantly protected from low-dose aerosol challenge with M. tuberculosis, even with CSU-F36 delivered in a simple depot material. This "natural adjuvant"-containing system could potentially bypass the need for more expensive TH1-inducing adjuvants and could be applied to many mycobacterial proteins to provide effective and cheap new vaccines against tuberculosis.

* Corresponding author. Mailing address: Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523. Phone: (970) 491-5777. Fax: (970) 491-5125. E-mail: ian.orme{at}colostate.edu

{triangledown} Published ahead of print on 16 May 2007.

{dagger} These authors contributed equally to this study.

Clinical and Vaccine Immunology, July 2007, p. 902-906, Vol. 14, No. 7
1071-412X/07/$08.00+0     doi:10.1128/CVI.00077-07
Copyright © 2007, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Gallorini, S., Berti, F., Mancuso, G., Cozzi, R., Tortoli, M., Volpini, G., Telford, J. L., Beninati, C., Maione, D., Wack, A. (2009). Toll-like receptor 2 dependent immunogenicity of glycoconjugate vaccines containing chemically derived zwitterionic polysaccharides. Proc. Natl. Acad. Sci. USA 106: 17481-17486 [Abstract] [Full Text]  
  • Rampini, S. K., Selchow, P., Keller, C., Ehlers, S., Bottger, E. C., Sander, P. (2008). LspA inactivation in Mycobacterium tuberculosis results in attenuation without affecting phagosome maturation arrest. Microbiology 154: 2991-3001 [Abstract] [Full Text]  
  • Wedlock, D. N., Denis, M., Painter, G. F., Ainge, G. D., Vordermeier, H. M., Hewinson, R. G., Buddle, B. M. (2008). Enhanced Protection against Bovine Tuberculosis after Coadministration of Mycobacterium bovis BCG with a Mycobacterial Protein Vaccine-Adjuvant Combination but Not after Coadministration of Adjuvant Alone. CVI 15: 765-772 [Abstract] [Full Text]  
  • Sieling, P. A., Hill, P. J., Dobos, K. M., Brookman, K., Kuhlman, A. M., Fabri, M., Krutzik, S. R., Rea, T. H., Heaslip, D. G., Belisle, J. T., Modlin, R. L. (2008). Conserved Mycobacterial Lipoglycoproteins Activate TLR2 but Also Require Glycosylation for MHC Class II-Restricted T Cell Activation. J. Immunol. 180: 5833-5842 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»